SCHEMBL29328043

SCHEMBL29328043

Cc1cc(C)n(-c2cccc(Oc3ccc4c5ccccc5n(-c5cc(-n6c7c(C)cccc7c7cccc(C)c76)ccn5)c4c3)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
POLB P06746 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPT P10636 4/20 0.33
TP53 P04637 2/20 0.33
SCN9A Q15858 2/20 0.32
SHMT2 P34897 1/20 0.32
TSHR P16473 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
LMNA P02545 1/20 0.31
ALKBH5 Q6P6C2 1/20 0.31
FTO Q9C0B1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16280316 0.93 SMN1; SMN2 (0.39) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL16280565 0.92 SMN1; SMN2 (0.38) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL16280194 0.87 SMN1; SMN2 (0.39) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL16280256 0.86 SMN1; SMN2 (0.38) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL29328052 0.85 ALKBH5 (0.33) ALKBH5FTONR1H2NR1H3
SCHEMBL16279900 0.85 SMN1; SMN2 (0.39) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL11969821 0.85 SMN1; SMN2 (0.40) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL29328098 0.85 NPC1 (0.32) SMN1; SMN2NPC1RAB9AALKBH5FTO
SCHEMBL16280039 0.85 SMN1; SMN2 (0.39) SMN1; SMN2POLBRXFP1ALDH1A1MAPT
SCHEMBL16280380 0.85 SMN1; SMN2 (0.39) SMN1; SMN2POLBRXFP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF ZHEJIANG HUAXIAN PHOTOELECTRICITY TECHNOLOGY CO., LTD (CN) 2024-07-18 US disclosed
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF ZHEJIANG HUAXIAN PHOTOELECTRICITY TECHNOLOGY CO., LTD (CN) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF LIG3, VIM, TRIM33 SMN1; SMN2 4447/4885POLB 665/4885RXFP1 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.